Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality
Overview
Authors
Affiliations
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of and vancomycin resistance in 40% of . Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs.
Todor S, Ichim C Children (Basel). 2025; 12(2).
PMID: 40003268 PMC: 11854176. DOI: 10.3390/children12020166.
Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children.
Hoshino W, da Silva A, Pignatari A, Gales A, Carlesse F Braz J Infect Dis. 2025; 29(2):104515.
PMID: 39985933 PMC: 11893299. DOI: 10.1016/j.bjid.2025.104515.
Castagnola E, Bagnasco F, Mesini A, Agyeman P, Ammann R, Arrabito M Antibiotics (Basel). 2025; 13(12.
PMID: 39766549 PMC: 11672620. DOI: 10.3390/antibiotics13121160.
Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan.
Murshed I, Zhao L, Zhang W, Yin Y, Li Y, Peng Y Front Cell Infect Microbiol. 2024; 14:1480952.
PMID: 39698316 PMC: 11652520. DOI: 10.3389/fcimb.2024.1480952.
Butters C, Grobler A, Rudkin A, Goh L, Werdenburg H, Hanna D PLoS One. 2024; 19(12):e0311523.
PMID: 39652544 PMC: 11627426. DOI: 10.1371/journal.pone.0311523.